<DOC>
	<DOCNO>NCT01395485</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics adolescent adult subject intermittent mild moderate persistent asthma .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics AMG 827 Adolescents With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male and/or female subject 12 &lt; 18 year age time randomization Male and/or female subject 18 50 year age ( inclusive ) time randomization Body weight â‰¥ 36 kg screen Intermittent mild moderate persistent asthma least past 3 month prior study enrollment ( defined 2004 Global Initiative Asthma [ GINA ] guideline . Experienced asthma exacerbation ( defined disease episode result treatment emergency room urgent care facility , episode treated oral corticosteroid ) 3 month prior study enrollment . Hospitalized asthma 6 month prior study enrollment ; ever intubate treatment asthma . Use oral corticosteroid within 3 month prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Single Dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>